By Ahmed Aboulenein
WASHINGTON, April 2 (Reuters) – President Donald Trump signed an executive order on Thursday imposing 100% tariffs on branded pharmaceuticals imported into the U.S. unless manufacturers agree to government drug pricing deals or commit to making their products domestically.
The move is intended to push drugmakers to onshore production and cut U.S. prescription drug prices. It offers exemptions and reduced rates through trade agreements, manufacturing commitments and most‑favored‑nation pricing pacts.
Here are some details:
(Reporting by Ahmed Aboulenein; Additional reporting by Ryan Jones; Editing by Caroline Humer, Daniel Wallis and David Gregorio)
